Interesting and Informative Biostuff
The information provided on our website, including videos, links to presentations from other organisations, is intended for general informational purposes only.
The views expressed in these materials are those of the individual contributors and do not necessarily reflect the official position of ABSANZ.
While we strive to provide accurate and up-to-date information, please be aware that regulations and legislative requirements can vary significantly between countries, states, and regions. It is essential for users to verify the applicability of any information to their specific jurisdiction and seek advice from local regulatory authorities or qualified professionals before making decisions based on the content presented.
The content provided on this website should not be construed as legal, regulatory, or expert advice. We recommend that individuals and organisations consult with appropriate professionals or authorities to ensure compliance with all relevant laws, standards, and regulations.
By accessing this website, you acknowledge that you are using the information at your own risk and that the website owners and contributors are not responsible for any errors, omissions, or consequences arising from the use of the provided materials.
WHO's Laboratory Biosecurity Guidance document
This current revision replaces the 1st edition originally published in 2006 and provides guidance on ways to work safely and securely with high-consequence material and biosecurity-relevant material and how to build capacity at institutional and national levels to address biological risks to ensure that scientific progress continues while minimizing risks to the community and environment.
A study on contaminant leakage from Airborne Infection Isolation room during medical staff entry; Implementation of walking motion on hypothetical human model in CFD simulation
A Review of Clinical Trials Involving Genetically Modified Bacteria, Bacteriophages and Their Associated Risk Assessments
This review article summarizes the United States Food and Drug Administration classification for investigational products (IPs) comprising bacteria or bacteriophages and provides an overview of clinical trials conducted to date involving genetically modified bacteria. The risk assessment for bacterial or bacteriophage-based IPs is discussed.
The risk assessment process for bacterial or bacteriophage-based IPs is different from that of gene expression vectors and mammalian cells. Greater consideration must be given to the attenuating mutations affecting virulence, replication competency, antibiotic susceptibility, and persistence in the environment. With the recent growth in clinical trials involving genetically modified bacteria, biosafety professionals and Institutional Biosafety Committees with responsibilities including oversight of clinical trials must become familiar with the associated risk assessment.
Authors: Paul Gulig, Scott Swindle, Mark Fields, and Daniel Eisenman https://orcid.org/0000-0002-6607-4497 daniel.eisenman@advarra.comAUTHORS INFO & AFFILIATIONS
Publication: Applied Biosafety
Strengthening laboratory biological risk management
On May 31, 2024, the World Health Assembly endorsed a resolution on strengthening laboratory biological risk management as a necessary health security capacity. It covers laboratory biosafety and biosecurity, referring to both unintentional and intentional exposure to or release of biological or other materials. The resolution calls on Member States to develop or update national plans to include biological risk mitigation and management, build capacity of human resources, and promote a risk-based approach and culture of biosafety and biosecurity. The resolution also calls on the Secretariat to provide technical assistance to Member States, monitor developments in this area, and convene discussions to develop standards.
Laboratory accidents and biocontainment breaches
International Atomic Energy Agency (IAEA)
Animal Production & Health Newsletter July 2023
Prevention of zoonotic spillover: From relying on response to reducing the risk at source
Prevention of zoonotic spillover: From relying on response to reducing the risk at source
Preventing COVID-19 From Airborne Transmission
Preventing COVID-19 infection from airborne transmission. Controlling the source, pathway, and receptor, in high-risk workplaces.
Presented by Kate Cole and Dr Julia Norris - AIOH
Laboratory Building
You can't always get what you want. Explaining how laboratories are designed.
Presented by Belinda Lees
NOTES FROM ANTARCTICA
Notes from Antarctica. An informative presentation by an expeditioner from the 1980's.
Presented by Neil Walls
Investigating mechanisms of aerosol generation from various laboratory accidents
FLOW Lab investigating mechanisms of aerosol generation from various laboratory accidents.